{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:20:22Z","timestamp":1793312422781,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Before the introduction of prostate MRI, prostate cancer screening relied on prostate-specific antigen (PSA) testing followed by a systematic biopsy. Although this approach reduced prostate cancer mortality in large, randomized screening trials, its net benefit was questionable because of substantial overdiagnosis. In response, more precise screening tools have been developed. Diagnostic studies demonstrate that MRI has a high sensitivity for clinically significant prostate cancer and a low sensitivity for low-grade cancer, making it well-suited as a triage before biopsy. Using MRI as the primary screening test increases detection of potentially clinically significant cancer, while sequential strategies\u2014such as those used in the STHLM3-MRI trial\u2014reduce the number of MRI scans, unnecessary biopsies and low-grade cancer diagnoses with maintained detection of clinically significant cancer. Several ongoing randomized trials now incorporate PSA-triggered MRI in repeated screening rounds. The Gothenburg 2 trial has reported that its MRI-targeted biopsy pathway halves low-grade cancer detection but misses a few clinically significant cancers. Proscreen evaluates a screening pathway with an ancillary kallikrein test to select men for MRI, PROBASE start age 45 years, and large-scale initiatives\u2014such as organized prostate cancer testing (OPT) programs\u2014evaluate real-world feasibility. Key challenges include optimizing MRI protocols, improving consistency in image interpretation, and reducing false-positive findings, particularly in younger men. Centralized reading, AI support, and refined risk stratification may enhance scalability. Accumulating evidence from ongoing trials and population-based programs suggests that MRI-based screening strategies improve the benefit-to-harm ratio in prostate cancer screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>This special report summarizes the evidence from ongoing and completed clinical trials on prostate cancer screening using MRI.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Across diagnostic and randomized screening trials, MRI-based pathways reduce low-grade cancer detection and biopsy rates while maintaining detection of clinically significant prostate cancer.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>MRI-based screening improves the benefit\u2013harm balance by avoiding unnecessary biopsies and overdiagnosis while maintaining early detection of aggressive prostate cancer, enabling safer, more precise population-level screening for men.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-026-12533-4","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T10:45:22Z","timestamp":1776336322000},"page":"6476-6486","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ongoing and completed clinical trials on prostate cancer screening using MRI"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4453-6718","authenticated-orcid":false,"given":"Jonas","family":"Wallstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"J\u00e4derling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Langkilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka","family":"Arnsrud Godtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Bratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Thimansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"12533_CR1","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schroder","year":"2009","unstructured":"Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320\u20131328","journal-title":"N Engl J Med"},{"key":"12533_CR2","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1097\/PAS.0b013e3182556dcd","volume":"36","author":"HM Ross","year":"2012","unstructured":"Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI (2012) Do adenocarcinomas of the prostate with Gleason score (GS) \u22646 have the potential to metastasize to lymph nodes? Am J Surg Pathol 36:1346\u20131352","journal-title":"Am J Surg Pathol"},{"key":"12533_CR3","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","volume":"393","author":"MJ Roobol","year":"2025","unstructured":"Roobol MJ, de Vos II, Mansson M et al (2025) European study of prostate cancer screening\u201423-year follow-up. N Engl J Med 393:1669\u20131680","journal-title":"N Engl J Med"},{"key":"12533_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/JU.0000000000002696","volume":"208","author":"M Franlund","year":"2022","unstructured":"Franlund M, Mansson M, Godtman RA et al (2022) Results from 22 years of followup in the Goteborg randomized population-based prostate cancer screening trial. J Urol 208:292\u2013300","journal-title":"J Urol"},{"key":"12533_CR5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1093\/jnci\/95.12.868","volume":"95","author":"G Draisma","year":"2003","unstructured":"Draisma G, Boer R, Otto SJ et al (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer. J Natl Cancer Inst 95:868\u2013878","journal-title":"J Natl Cancer Inst"},{"key":"12533_CR6","doi-asserted-by":"crossref","unstructured":"Bratt O, Auvinen A, Arnsrud Godtman R et al (2023) Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps. BMJ Oncol 2:e000039","DOI":"10.1136\/bmjonc-2023-000039"},{"key":"12533_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2471\/BLT.07.050112","volume":"86","author":"A Andermann","year":"2008","unstructured":"Andermann A, Blancquaert I, Beauchamp S, Dery V (2008) Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 86:317\u2013319","journal-title":"Bull World Health Organ"},{"key":"12533_CR8","doi-asserted-by":"publisher","unstructured":"Ahn H, Park MY, Shin JI et al (2025) Fast biparametric versus multiparametric magnetic resonance imaging for triage of men with elevated prostate-specific antigen: the PRO-TRIAGE prospective comparative trial. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2025.07.001","DOI":"10.1016\/j.euo.2025.07.001"},{"key":"12533_CR9","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.euo.2023.11.003","volume":"7","author":"RA Godtman","year":"2024","unstructured":"Godtman RA, Pettersson C, Svensson L et al (2024) Men\u2019s acceptance of screening for prostate cancer with prostate-specific antigen, magnetic resonance imaging, and prostate biopsy. Eur Urol Oncol 7:553\u2013562","journal-title":"Eur Urol Oncol"},{"key":"12533_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389:815\u2013822","journal-title":"Lancet"},{"key":"12533_CR11","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378:1767\u20131777","journal-title":"N Engl J Med"},{"key":"12533_CR12","first-page":"CD012663","volume":"4","author":"FH Drost","year":"2019","unstructured":"Drost FH, Osses DF, Nieboer D et al (2019) Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev 4:CD012663","journal-title":"Cochrane Database Syst Rev"},{"key":"12533_CR13","doi-asserted-by":"crossref","unstructured":"Cornford P, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: Screening, diagnosis, and local treatment with curative intent. Eur Urol 86:148\u2013163","DOI":"10.1016\/j.eururo.2024.03.027"},{"key":"12533_CR14","doi-asserted-by":"publisher","first-page":"e231130","DOI":"10.1148\/radiol.231130","volume":"309","author":"F Giganti","year":"2023","unstructured":"Giganti F, Ng A, Asif A et al (2023) Global variation in magnetic resonance imaging quality of the prostate. Radiology 309:e231130","journal-title":"Radiology"},{"key":"12533_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.euros.2025.05.008","volume":"77","author":"J Wallstrom","year":"2025","unstructured":"Wallstrom J, Alterbeck M, Godtman RA, Bratt O, Jiborn T, Thimansson E (2025) A comparison of magnetic resonance imaging assessment and biopsy outcomes with and without central review in two Swedish regional organized prostate cancer testing programs. Eur Urol Open Sci 77:32\u201338","journal-title":"Eur Urol Open Sci"},{"key":"12533_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76:340\u2013351","journal-title":"Eur Urol"},{"key":"12533_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.eururo.2023.09.027","volume":"85","author":"M Boschheidgen","year":"2024","unstructured":"Boschheidgen M, Albers P, Schlemmer HP et al (2024) Multiparametric magnetic resonance imaging in prostate cancer screening at the age of 45 years: results from the first screening round of the PROBASE trial. Eur Urol 85:105\u2013111","journal-title":"Eur Urol"},{"key":"12533_CR18","doi-asserted-by":"publisher","first-page":"4908","DOI":"10.1007\/s00330-020-07545-7","volume":"31","author":"V Bura","year":"2021","unstructured":"Bura V, Caglic I, Snoj Z et al (2021) MRI features of the normal prostatic peripheral zone: the relationship between age and signal heterogeneity on T2WI, DWI, and DCE sequences. Eur Radiol 31:4908\u20134917","journal-title":"Eur Radiol"},{"key":"12533_CR19","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein JI, Egevad L, Amin MB et al (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40:244\u2013252","journal-title":"Am J Surg Pathol"},{"key":"12533_CR20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2020.7456","volume":"7","author":"D Eldred-Evans","year":"2021","unstructured":"Eldred-Evans D, Burak P, Connor MJ et al (2021) Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study. JAMA Oncol 7:395\u2013402","journal-title":"JAMA Oncol"},{"key":"12533_CR21","doi-asserted-by":"publisher","first-page":"e000057","DOI":"10.1136\/bmjonc-2023-000057","volume":"2","author":"CM Moore","year":"2023","unstructured":"Moore CM, Frangou E, McCartan N et al (2023) Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study. BMJ Oncol 2:e000057","journal-title":"BMJ Oncol"},{"key":"12533_CR22","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.euf.2024.02.006","volume":"10","author":"C Wetterauer","year":"2024","unstructured":"Wetterauer C, Matthias M, Pueschel H et al (2024) Opportunistic prostate cancer screening with biparametric magnetic resonance imaging (VISIONING). Eur Urol Focus 10:332\u2013338","journal-title":"Eur Urol Focus"},{"key":"12533_CR23","doi-asserted-by":"publisher","first-page":"e059482","DOI":"10.1136\/bmjopen-2021-059482","volume":"12","author":"R Nam","year":"2022","unstructured":"Nam R, Patel C, Milot L et al (2022) Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial. BMJ Open 12:e059482","journal-title":"BMJ Open"},{"key":"12533_CR24","doi-asserted-by":"crossref","unstructured":"Messina E, Borrelli A, Sciarra A et al (2026) Primary noncontrast magnetic resonance imaging for prostate cancer screening: a randomized clinical trial (PROSA). Eur Urol 89:246\u2013257","DOI":"10.1016\/j.eururo.2025.11.024"},{"key":"12533_CR25","doi-asserted-by":"crossref","unstructured":"Gulati R, Jiao B, Al-Faouri R et al (2024) Lifetime health and economic outcomes of biparametric magnetic resonance imaging as first-line screening for prostate cancer: a decision model analysis. Ann Intern Med 177:871\u2013881","DOI":"10.7326\/M23-1504"},{"key":"12533_CR26","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/21681805.2021.1881612","volume":"55","author":"K Kohestani","year":"2021","unstructured":"Kohestani K, Mansson M, Arnsrud Godtman R et al (2021) The GOTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate. Scand J Urol 55:116\u2013124","journal-title":"Scand J Urol"},{"key":"12533_CR27","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","volume":"387","author":"J Hugosson","year":"2022","unstructured":"Hugosson J, M\u00e5nsson M, Wallstr\u00f6m J et al (2022) Prostate cancer screening with PSA and MRI followed by targeted biopsy only. N Engl J Med 387:2126\u20132137","journal-title":"N Engl J Med"},{"key":"12533_CR28","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1056\/NEJMoa2406050","volume":"391","author":"J Hugosson","year":"2024","unstructured":"Hugosson J, Godtman RA, Wallstrom J et al (2024) Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med 391:1083\u20131095","journal-title":"N Engl J Med"},{"key":"12533_CR29","doi-asserted-by":"crossref","unstructured":"Auvinen A, Tammela TLJ, Mirtti T et al (2024) Prostate cancer screening with PSA, kallikrein panel, and MRI: the ProScreen randomized trial. JAMA 331:1452\u20131459","DOI":"10.1001\/jama.2024.3841"},{"key":"12533_CR30","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ijc.33940","volume":"150","author":"C Arsov","year":"2022","unstructured":"Arsov C, Albers P, Herkommer K et al (2022) A randomized trial of risk-adapted screening for prostate cancer in young men\u2014results of the first screening round of the PROBASE trial. Int J Cancer 150:1861\u20131869","journal-title":"Int J Cancer"},{"key":"12533_CR31","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa2100852","volume":"385","author":"M Eklund","year":"2021","unstructured":"Eklund M, Jaderling F, Discacciati A et al (2021) MRI-targeted or standard biopsy in prostate cancer screening. N Engl J Med 385:908\u2013920","journal-title":"N Engl J Med"},{"key":"12533_CR32","doi-asserted-by":"publisher","first-page":"e2354577","DOI":"10.1001\/jamanetworkopen.2023.54577","volume":"7","author":"T Nordstrom","year":"2024","unstructured":"Nordstrom T, Annerstedt M, Glaessgen A et al (2024) Repeated prostate cancer screening using prostate-specific antigen testing and magnetic resonance imaging: a secondary analysis of the STHLM3-MRI randomized clinical trial. JAMA Netw Open 7:e2354577","journal-title":"JAMA Netw Open"},{"key":"12533_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.eururo.2024.09.035","volume":"87","author":"JJ Twilt","year":"2025","unstructured":"Twilt JJ, Saha A, Bosma JS et al (2025) Evaluating biparametric versus multiparametric magnetic resonance imaging for diagnosing clinically significant prostate cancer: an international, paired, noninferiority, confirmatory observer study. Eur Urol 87:240\u2013250","journal-title":"Eur Urol"},{"key":"12533_CR34","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1001\/jama.2025.13722","volume":"334","author":"A Ng","year":"2025","unstructured":"Ng A, Asif A, Agarwal R et al (2025) Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial. JAMA 334:1170\u20131179","journal-title":"JAMA"},{"key":"12533_CR35","doi-asserted-by":"publisher","first-page":"e2432328","DOI":"10.2214\/AJR.24.32328","volume":"224","author":"E Salinas-Miranda","year":"2025","unstructured":"Salinas-Miranda E, Birosh A, McInnes MDF et al (2025) NPV of biparametric and multiparametric prostate MRI: a comparative systematic review and meta-analysis. AJR Am J Roentgenol 224:e2432328","journal-title":"AJR Am J Roentgenol"},{"key":"12533_CR36","doi-asserted-by":"publisher","first-page":"8692","DOI":"10.1007\/s00330-021-07907-9","volume":"31","author":"J Wallstrom","year":"2021","unstructured":"Wallstrom J, Geterud K, Kohestani K et al (2021) Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Goteborg prostate cancer screening 2 trial. Eur Radiol 31:8692\u20138702","journal-title":"Eur Radiol"},{"key":"12533_CR37","doi-asserted-by":"crossref","unstructured":"de Rooij M, Allen C, Twilt JJ et al (2024) PI-QUAL version 2: an update of a standardised scoring system for the assessment of image quality of prostate MRI. Eur Radiol 34:7068\u20137079","DOI":"10.1007\/s00330-024-10795-4"},{"key":"12533_CR38","doi-asserted-by":"publisher","first-page":"100635","DOI":"10.1016\/j.ejro.2025.100635","volume":"14","author":"AM Pausch","year":"2025","unstructured":"Pausch AM, Fillebock V, Elsner C, Rupp NJ, Eberli D, Hotker AM (2025) Ultra-fast biparametric MRI in prostate cancer assessment: diagnostic performance and image quality compared to conventional multiparametric MRI. Eur J Radiol Open 14:100635","journal-title":"Eur J Radiol Open"},{"key":"12533_CR39","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/jmri.29108","volume":"60","author":"N Mir","year":"2024","unstructured":"Mir N, Fransen SJ, Wolterink JM, Futterer JJ, Simonis FFJ (2024) Recent developments in speeding up prostate MRI. J Magn Reson Imaging 60:813\u2013826","journal-title":"J Magn Reson Imaging"},{"key":"12533_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1148\/radiol.2017170129","volume":"285","author":"CK Kuhl","year":"2017","unstructured":"Kuhl CK, Bruhn R, Kramer N, Nebelung S, Heidenreich A, Schrading S (2017) Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology 285:493\u2013505","journal-title":"Radiology"},{"key":"12533_CR41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.euo.2021.03.007","volume":"4","author":"F Russo","year":"2021","unstructured":"Russo F, Mazzetti S, Regge D et al (2021) Diagnostic accuracy of single-plane biparametric and multiparametric magnetic resonance imaging in prostate cancer: a randomized noninferiority trial in biopsy-naive men. Eur Urol Oncol 4:855\u2013862","journal-title":"Eur Urol Oncol"},{"key":"12533_CR42","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1007\/s00330-020-06929-z","volume":"30","author":"M de Rooij","year":"2020","unstructured":"de Rooij M, Israel B, Tummers M et al (2020) ESUR\/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists\u2019 training. Eur Radiol 30:5404\u20135416","journal-title":"Eur Radiol"},{"key":"12533_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.euros.2025.03.014","volume":"75","author":"R Al-Monajjed","year":"2025","unstructured":"Al-Monajjed R, Schimmoller L, Radtke JP et al (2025) Characterisation of multiparametric magnetic resonance imaging of the prostate in younger men with normal prostate-specific antigen within the PROBASE study. Eur Urol Open Sci 75:94\u2013100","journal-title":"Eur Urol Open Sci"},{"key":"12533_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.euo.2021.09.001","volume":"5","author":"J Wallstrom","year":"2022","unstructured":"Wallstrom J, Geterud K, Kohestani K et al (2022) Prostate cancer screening with magnetic resonance imaging: results from the second round of the Goteborg prostate cancer screening 2 trial. Eur Urol Oncol 5:54\u201360","journal-title":"Eur Urol Oncol"},{"key":"12533_CR45","doi-asserted-by":"publisher","first-page":"e2515672","DOI":"10.1001\/jamanetworkopen.2025.15672","volume":"8","author":"JJ Twilt","year":"2025","unstructured":"Twilt JJ, Saha A, Bosma JS et al (2025) AI-assisted vs unassisted identification of prostate cancer in magnetic resonance images. JAMA Netw Open 8:e2515672","journal-title":"JAMA Netw Open"},{"key":"12533_CR46","doi-asserted-by":"publisher","first-page":"816","DOI":"10.2340\/1651-226X.2024.40475","volume":"63","author":"E Thimansson","year":"2024","unstructured":"Thimansson E, Zackrisson S, Jaderling F et al (2024) A pilot study of AI-assisted reading of prostate MRI in organized prostate cancer testing. Acta Oncol 63:816\u2013821","journal-title":"Acta Oncol"},{"key":"12533_CR47","doi-asserted-by":"publisher","unstructured":"Langkilde F, Gren M, Wallstrom J, Kuczera S, Maier SE (2025) Evaluation of AI for prostate cancer detection in biparametric-MRI screening population data. Eur Radiol. https:\/\/doi.org\/10.1007\/s00330-025-12198-5","DOI":"10.1007\/s00330-025-12198-5"},{"key":"12533_CR48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.eururo.2023.08.002","volume":"84","author":"H Van Poppel","year":"2023","unstructured":"Van Poppel H, Roobol MJ, Chandran A (2023) Early detection of prostate cancer in the European Union: combining forces with PRAISE-U. Eur Urol 84:519\u2013522","journal-title":"Eur Urol"},{"key":"12533_CR49","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2340\/sju.v60.43809","volume":"60","author":"O Bratt","year":"2025","unstructured":"Bratt O, Butt ST, Carlsson C et al (2025) Swedish regional population-based organised prostate cancer testing: why, what and how? Scand J Urol 60:97\u2013104","journal-title":"Scand J Urol"},{"key":"12533_CR50","doi-asserted-by":"crossref","unstructured":"Alterbeck M, Jarbur E, Thimansson E et al (2022) Designing and implementing a population-based organised prostate cancer testing programme. Eur Urol Focus 8:1568\u20131574","DOI":"10.1016\/j.euf.2022.06.008"},{"key":"12533_CR51","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.11.013","volume":"85","author":"O Bratt","year":"2024","unstructured":"Bratt O, Godtman RA, Jiborn T et al (2024) Population-based organised prostate cancer testing: results from the first invitation of 50-year-old men. Eur Urol 85:207\u2013214","journal-title":"Eur Urol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12533-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-026-12533-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-026-12533-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:04:20Z","timestamp":1783433060000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-026-12533-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":51,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["12533"],"URL":"https:\/\/doi.org\/10.1007\/s00330-026-12533-4","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Jonas Wallstr\u00f6m.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required for this study because this is a review paper using only previously published data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was not required because this is a review paper using only previously published data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable (review paper).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}